Cirrhosis News and Research

Latest Cirrhosis News and Research

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

New study sheds more light on level of alcohol consumption among people with hepatitis C

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use.

11 May 2016

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity. Hepatocellular carcinoma is one of the most common forms of cancer, and the primary cause has been attributed to liver fibrosis by chemical toxins, which is followed by liver cirrhosis.

9 May 2016

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology.

5 May 2016

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

27 Apr 2016

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers.

27 Apr 2016

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

Acute liver failure after massive hepatectomy improves with liver cell transplantation

Liver failure often occurs after an extensive hepatectomy, which is the surgical resection of the liver. While liver cell transplantation is a useful therapy for acute liver failure after massive hepatectomy, when cells are transplanted through liver portal veins raises the risk of embolization, such as the formation and movement of a blood clot, often with fatal consequences.

26 Apr 2016

New therapy strategy for liver disease shows initial measureable success with norUrso

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid (norUrso).

19 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Adding coffee to the diet of people with non-alcoholic fatty liver disease (NAFLD) could help reverse the condition, according to a new study conducted in mice presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

Hospitals could reduce burden of alcohol-related liver disease through universal screening procedure

The growing burden of alcohol-related liver disease (ARLD) could be reduced if hospitals introduced a simple universal screening procedure for those attending acute and emergency hospital settings, according to a new study shared today at The International Liver Congress in Barcelona, Spain.

13 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Cirrhosis News and Research

Latest Cirrhosis News and Research

Clinical study shows sitagliptin drug not effective in treating NAFLD

New study sheds more light on level of alcohol consumption among people with hepatitis C

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Regular aspirin use may help reduce risk of bile duct cancer

Acute liver failure after massive hepatectomy improves with liver cell transplantation

New therapy strategy for liver disease shows initial measureable success with norUrso

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Hepatitis C treatment can be provided safely, effectively within community-based setting

Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Hospitals could reduce burden of alcohol-related liver disease through universal screening procedure

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

New research shows type 2 diabetes as important risk factor for chronic liver disease

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Cuts in alcohol taxation could increase alcohol-related deaths in England

3D MRE offers accurate non-invasive method to detect advanced fibrosis

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in